Company Listing
Wilson Therapeutics

Wilson is developing a novel de-coppering agent as a new treatment for Wilson disease. This is a rare genetic disorder that prevents the body from regulating copper levels and can lead to serious liver and brain damage. The product works by removing the abnormal accumulation of copper from the liver, brain and other organs. Existing treatments are inadequate and frequently have debilitating side-effects. Wilson went public in May 2016.

BACK
Location
Stockholm, Sweden
CEO
Jonas Hansson
Abingworth Partner
Genghis Lloyd-Harris
Website Address

Home

About Us

  1. About Us
  2. Our Team
  3. Transatlantic Reach
  4. Funds

Strategy

  1. Our Strategy
  2. Venture Capital
  3. Clinical Co‑development
  4. VIPEs
  5. Public Markets

Portfolio

  1. Portfolio Companies
  2. Case Studies

Media Centre

  1. Recent News
  2. Archived News
  3. Film

Contact

  1. Contact Us
  2. Send Us Your Proposal
Company Listing

Wilson is developing a novel de-coppering agent as a new treatment for Wilson disease. This is a rare genetic disorder that prevents the body from regulating copper levels and can lead to serious liver and brain damage. The product works by removing the abnormal accumulation of copper from the liver, brain and other organs. Existing treatments are inadequate and frequently have debilitating side-effects. Wilson went public in May 2016.

Location
Stockholm, Sweden
CEO
Jonas Hansson
Abingworth Partner
Genghis Lloyd-Harris
Website Address
BACK
 
Copyright Abingworth 2017